This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AcelRx Pharmaceuticals Provides Update On Its Patent Portfolio For Zalviso™ And Its Proprietary Platform Technologies

REDWOOD CITY, Calif., Oct. 8, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update regarding its growing patent estate which totals 19 issued patents worldwide.  These issued patents cover AcelRx's sufentanil Nanotab™, medication delivery devices and platform technology, and includes nine issued U.S. patents, three issued European patents with 27 national registrations and seven issued patents in other international territories including Japan and China.  These issued patents are expected to provide coverage through 2027 – 2031.

"Over the last year and a half, we have established a broad portfolio of both drug and device patents covering the substantial majority of the potential markets for our products. Particularly, we believe we have established strong and enduring protection in both the U.S. and Europe, which are our initial areas of commercial focus," stated Richard King, president and CEO of AcelRx. "We anticipate further expansion of AcelRx's patent estate resulting from our pursuit of 13 U.S. patent applications and an additional 40 foreign national applications, which, if issued, will further strengthen the protection for our product pipeline."

Issued U.S. Patents in 2013

U.S. patent #8,357,114 entitled "Drug dispensing device with flexible push rod" relates to devices for dispensing a sublingual drug dosage form to a patient through a curved passage using a flexible rod to push a tablet. Issued January 22, 2013, with coverage anticipated through 2027.

U.S. patent #8,499,966 entitled "Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms" relates to a method of administering small, bioadhesive drug tablets and includes moving an end portion of a delivery member. Issued August 6, 2013, with coverage anticipated through 2028.

U.S. patent #8,535,714 entitled "Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain" relates to specific features of the sublingual sufentanil tablet formulation, including particular pharmacokinetic properties. Issued September 17, 2013, with coverage anticipated through 2027.

U.S. patent #8,548,623 entitled "Storage and dispensing devices for administration of oral transmucosal dosage forms" relates to key features of a simplified multiple dose delivery device suitable for use in an outpatient setting. Issued October 1, 2013, with coverage anticipated through 2031.

Issued European and International Patents in 2013

European patent #EP1973593B1 entitled "Drug storage and dispensing devices and systems comprising the same" relates to dispensing devices for administration of drug dosage forms and systems comprising them, and in particular a dispensing device for oral transmucosal administration of a drug dosage tablet to a subject including a means for detecting the identity of the patient, a lock-out feature and a means to prevent unauthorized access to stored drugs. Issued April 10, 2013 with coverage anticipated through 2027.

Additionally, AcelRx currently has two issued patents in China with coverage anticipated through 2028, and three issued patents in Japan with coverage anticipated through 2027. Further, we have received one patent in each Mexico and New Zealand with coverage anticipated through 2029.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso™, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps.  AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval.  AcelRx has also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from the U.S. Army Medical Research and Materiel Command.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs, please visit www.acelrx.com.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs